At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.
Steven R. Sarkisian Jr., MD, ABO
Advertisement
Articles by Steven R. Sarkisian Jr., MD, ABO
Advertisement
Latest Updated Articles
Nitric Oxide and Its Important Role in the Trabecular Meshwork of Glaucoma PatientsPublished: December 21st 2018 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
PRIMAvera study: Central vision improvement with subretinal implant
4
What changed in glaucoma care in 2025: Surgeon perspective
5